Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Dividend stocks offer long-term investors unique benefits.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including ...

HOUSTON (AP) — Vertex Energy Inc. VTNR) on Thursday reported a loss of $53.8 million in its second quarter. The Houston-based company said it had a loss of 58 cents per share. HOUSTON ...

This was the stock's second consecutive day of losses.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing ...